Schrödinger, Inc. (NASDAQ:SDGR) Receives Average Rating of “Buy” from Brokerages

Schrödinger, Inc. (NASDAQ:SDGR) has been given an average recommendation of “Buy” by the eight analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $33.00.

A number of research firms have recently commented on SDGR. KeyCorp lifted their price target on shares of Schrödinger from $30.00 to $32.00 and gave the company an “overweight” rating in a research report on Wednesday, April 16th. Piper Sandler dropped their target price on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, February 27th.

Insider Buying and Selling

In related news, CFO Geoffrey Craig Porges sold 5,491 shares of Schrödinger stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $21.76, for a total transaction of $119,484.16. Following the sale, the chief financial officer now directly owns 27,544 shares of the company’s stock, valued at $599,357.44. This trade represents a 16.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Karen Akinsanya sold 16,723 shares of the business’s stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $25.09, for a total value of $419,580.07. Following the transaction, the insider now owns 15,625 shares in the company, valued at $392,031.25. This represents a 51.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Hong Kong Ltd acquired a new position in shares of Schrödinger in the 4th quarter valued at $27,000. Paradigm Asset Management Co. LLC acquired a new position in Schrödinger in the fourth quarter worth about $50,000. GAMMA Investing LLC lifted its stake in Schrödinger by 87.5% during the fourth quarter. GAMMA Investing LLC now owns 2,796 shares of the company’s stock worth $54,000 after purchasing an additional 1,305 shares during the period. KBC Group NV boosted its holdings in Schrödinger by 73.9% during the fourth quarter. KBC Group NV now owns 4,361 shares of the company’s stock valued at $84,000 after purchasing an additional 1,853 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Schrödinger in the 4th quarter valued at approximately $199,000. 79.05% of the stock is owned by institutional investors.

Schrödinger Trading Up 2.1 %

Shares of NASDAQ:SDGR opened at $25.75 on Monday. Schrödinger has a 1 year low of $16.60 and a 1 year high of $28.47. The firm has a fifty day moving average price of $22.01 and a 200 day moving average price of $21.02. The stock has a market capitalization of $1.88 billion, a PE ratio of -11.00 and a beta of 1.77.

Schrödinger (NASDAQ:SDGR) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The company had revenue of $88.32 million for the quarter, compared to the consensus estimate of $83.20 million. On average, sell-side analysts forecast that Schrödinger will post -2.37 earnings per share for the current fiscal year.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.